Final answer:
Drugs prohibited from distribution via ADC are subject to continuous monitoring and evaluation to ensure patient safety.
Step-by-step explanation:
According to the information provided, there is no specific mention of a P&T (Pharmacy & Therapeutics) committee's review frequency for drugs prohibited from distribution via ADC (Automated Dispensing Cabinet). However, as a general practice, drugs that are prohibited are closely monitored for safety and effectiveness by regulatory bodies.
The sponsors of the drugs are required to report any adverse drug events they become aware of to the FDA. Additionally, a pharmacovigilance system is in place to continually evaluate the long-term safety and the effect of the drug in specific patient subgroups.
Therefore, while the exact frequency may vary, it can be concluded that drugs prohibited from distribution via ADC are subject to continuous monitoring and evaluation to ensure patient safety.